News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
23,470 Results
Type
Article (4753)
Company Profile (3)
Press Release (18714)
Section
Business (8622)
Career Advice (115)
Deals (1404)
Drug Delivery (14)
Drug Development (4141)
Employer Resources (20)
FDA (731)
Job Trends (1051)
News (14375)
Policy (1891)
Tag
Academia (110)
Alliances (1997)
Alzheimer's disease (32)
Antibody-drug conjugate (ADC) (17)
Approvals (719)
Bankruptcy (8)
Best Places to Work (667)
Breast cancer (16)
Cancer (70)
Cardiovascular disease (14)
Career advice (90)
CAR-T (7)
Cell therapy (15)
Clinical research (2750)
Collaboration (23)
COVID-19 (920)
C-suite (16)
Data (39)
Diagnostics (180)
Diversity, equity & inclusion (7)
Drug pricing (19)
Duchenne muscular dystrophy (15)
Earnings (1914)
Employer resources (19)
Events (1881)
Executive appointments (48)
FDA (753)
Funding (19)
Gene editing (8)
Gene therapy (29)
GLP-1 (73)
Government (501)
Healthcare (633)
Infectious disease (941)
Inflammatory bowel disease (10)
Interviews (12)
IPO (354)
IRA (13)
Job creations (413)
Job search strategy (85)
Layoffs (45)
Legal (544)
Lung cancer (9)
Lymphoma (9)
Medical device (83)
Medtech (83)
Mergers & acquisitions (1057)
Metabolic disorders (29)
Neuroscience (41)
NextGen: Class of 2025 (227)
Non-profit (107)
Northern California (49)
Obesity (17)
Opinion (44)
Patents (12)
People (4061)
Phase I (815)
Phase II (1098)
Phase III (1310)
Pipeline (31)
Podcasts (20)
Policy (21)
Postmarket research (203)
Preclinical (236)
Prostate cancer (7)
Rare diseases (27)
Real estate (244)
Recruiting (7)
Regulatory (997)
Research institute (129)
Resumes & cover letters (21)
RSV (19)
Sickle cell disease (11)
Southern California (26)
Startups (287)
The Weekly (20)
United States (370)
Vaccines (341)
Weight loss (22)
Date
Today (5)
Last 7 days (27)
Last 30 days (94)
Last 365 days (1105)
2025 (117)
2024 (1090)
2023 (1160)
2022 (2821)
2021 (2692)
2020 (2119)
2019 (1257)
2018 (1059)
2017 (1257)
2016 (1142)
2015 (1414)
2014 (862)
2013 (730)
2012 (921)
2011 (1019)
2010 (752)
Location
Africa (85)
Alabama (8)
Asia (1465)
Australia (198)
California (85)
Canada (24)
China (9)
Connecticut (19)
Europe (4005)
Florida (12)
Japan (8)
Maryland (18)
Massachusetts (76)
New Jersey (15)
New York (80)
North Carolina (9)
Northern California (49)
Pennsylvania (22)
South America (80)
Southern California (26)
Washington State (9)
23,470 Results for "pfizer".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Pfizer Sees Path to Braftovi’s Full Approval With Phase III CRC Data
Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the way for its full approval for the treatment of certain colorectal cancers, according to the company.
February 3, 2025
·
2 min read
·
Tristan Manalac
Bladder cancer
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor indicated in combination with BCG for high-risk non-muscle invasive bladder cancer patients who had not previously undergone BCG treatment.
January 10, 2025
·
2 min read
·
Tristan Manalac
Cancer
BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that could position them as new standards of care in certain subtypes of metastatic colorectal cancer.
January 27, 2025
·
2 min read
·
Tristan Manalac
Earnings
Pfizer Eyes Deals up to $15B, With ‘Fruitful’ China Discussions Ongoing
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.
February 4, 2025
·
4 min read
·
Annalee Armstrong
Vaccines
GSK, Pfizer RSV Shots Required to Carry Guillain-Barré Syndrome Warnings
A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s Arexvy and Pfizer’s Abrysvo, prompting the regulator to require adjustments to the vaccines’ labels.
January 8, 2025
·
2 min read
·
Tristan Manalac
Business
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”
January 15, 2025
·
1 min read
·
Heather McKenzie
Business
Pfizer Gets Breather From Starboard’s Ongoing Assault
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by its current leadership. But
Bloomberg
reports it has missed the deadline for nominating a director to the pharma’s board.
January 28, 2025
·
2 min read
·
Tristan Manalac
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of breast cancer.
December 12, 2024
·
1 min read
·
Annalee Armstrong
Gene therapy
Sangamo’s Stock Plummets as Pfizer Axes Hemophilia Gene Therapy Pact
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments from Pfizer.
January 2, 2025
·
2 min read
·
Nick Paul Taylor
Drug development
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy,
BioSpace
looks at five investigational drugs currently making their way through the pipeline.
October 21, 2024
·
4 min read
·
Kate Goodwin
1 of 2,347
Next
